News

The Scottish Medicines Consortium (SMC) has added Ongentys (opicapone) — an add-on oral therapy to levodopa/Dopa decarboxylase inhibitors regimens (such as carbidopa) — to the list of medications available through the country’s National Health Service (NHS) to Parkinson’s patients experiencing ‘off’ periods. The decision comes more than five…

The Parkinson’s and Movement Disorder Center at the Queen’s Medical Center will use a $387,000 Michael J. Fox Foundation (MJFF) grant to study disparities in Parkinson’s disease care among Asian Americans, native Hawaiians, and Pacific Islanders, and to identify better approaches. The project is titled “Disparities in Care of…

L-dopa or levodopa, a standard treatment for Parkinson’s disease, forms a stable complex with iron and siderocalin, a protein involved in iron uptake by cells and found at higher levels in a brain region largely affected by Parkinson’s, a study shows. These early findings suggest that the formation…

The first patient has been treated in BioVie’s Phase 2 clinical trial assessing the impact of its investigational therapy, NE3107, on the motor symptoms of Parkinson’s disease. Study results for the Phase 2 trial, known as NM201, are expected by the end of 2022. “Enrollment of the first…

A new training program, the Bachmann-Strauss Fellowship in Dystonia Research aims to grow the number of researchers focused on the movement disorder known as dystonia. Launched by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the fellowship will support specialized training for those dedicated to investigating the causes…

Regular and sustained physical activity, including daily pursuits such as walking or gardening, may help slow the progression of Parkinson’s in people with early-stage disease, a long-term follow-up study suggests. Patients who exercised regularly over five years showed better motor and cognitive outcomes. “Our results are exciting, because they suggest it…

A first patient in Canada has been dosed in a Phase 1 clinical trial of DA01, a cell-based investigational therapy for advanced Parkinson’s disease by BlueRock Therapeutics. The therapy consists of surgically injecting neurons (nerve cells) that make dopamine — and which are damaged and die with Parkinson’s — into…

The U.S. Food and Drug Administration (FDA) has issued a partial clinical hold in response to an application by Yumanity Therapeutics requesting permission to begin clinical testing in the U.S. of YTX-7739 for Parkinson’s disease. With this decision, the FDA is allowing Yumanity to conduct a planned clinical…

The protein alpha-synuclein, which has a well-established role in the development of Parkinson’s disease, is necessary for the body to mount a normal immune response against infections. “This study provides further evidence that αS [alpha-synuclein], the protein intimately linked with the pathogenesis of PD [Parkinson’s disease], is a critical…

Green Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in people with early-stage Parkinson’s disease, according to a press release. This follows the acceptance of Green Valley‘s investigational new drug (IND) application by the U.S Food and Drug…